GV (Google Ventures)

Activity from announced rounds

Activity in this selectionOct 15, 2026 · Biotech · Jul 18, 2026

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
3
Confirmed lead rounds
1
1 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$848M
3 disclosed · full round size, not this investor’s share

By stage

Series C+2
Undisclosed1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in this selection
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Lead
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed